GlassScriptPhysician profile
James M Martin
NPI 1558708693
$55,851.49
in general payments reported to CMS, 2019-2025
25 companies · $2,277 in 2025
The $2,277 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $20.14 · 2021: $281 · 2022: $302 · 2023: $33K · 2024: $20K · 2025: $2,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $2,588 · Consulting Fee: $1,928 · Travel and Lodging: $842 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,682.50 |
| Food and Beverage | $2,587.80 |
| Consulting Fee | $1,928.00 |
| Travel and Lodging | $841.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19,253.88 | 2024 | |
| Stemline Therapeutics INC. | $18,541.77 | 2023 | Orserdu |
| Seagen INC. | $14,226.82 | 2022-2023 | Tukysa |
| Genzyme Corporation | $2,219.60 | 2025 | |
| Incyte Corporation | $652.17 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Amgen INC. | $265.58 | 2024 | Blincyto, Kyprolis |
| Beigene USA, INC. | $139.17 | 2024 | Brukinsa |
| Gilead Sciences, INC. | $122.88 | 2023 | Trodelvy |
| Janssen Biotech, INC. | $109.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.40 | 2021-2024 | |
| Daiichi Sankyo INC. | $45.62 | 2020-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $30.57 | 2024 | Fruzaqla |
| Lilly USA, LLC | $24.84 | 2024 | Verzenio |
| Eisai INC. | $22.37 | 2024 | |
| Glaxosmithkline, LLC. | $19.81 | 2024 | Ojjaara |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.31 | 2024 | Tecentriq |
| Jazz Pharmaceuticals INC. | $17.68 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.46 | 2023 | |
| Celgene Corporation | $15.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.74 | 2024 | Imfinzi |
| Rigel Pharmaceuticals, INC. | $13.89 | 2024 | Rezlidhia, Tavalisse |
| Springworks Therapeutics, INC. | $13.79 | 2024 | Ogsiveo |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.